OneCell Diagnostics is now 1Cell.Ai
With the power of data and AI to make effective treatment decisions.
Transforming Cancer Care—One Cell at a Time
At 1Cell.Ai, we are transforming cancer diagnostics and care by combining cutting-edge molecular science with advanced AI technology. Our next-generation, single-cell multi-omics platform delivers real-time, precision insights—empowering clinicians, researchers, and biopharma partners to make smarter, faster decisions.
Our Mission
We are committed to making precision oncology accessible, actionable, and affordable. By fusing scientific rigor with AI-powered technology, we deliver solutions that support earlier detection, personalized treatment, and continuous monitoring.
Traditional cancer diagnostics often miss key molecular signals—but OneCell Ai’s breakthrough AI-driven genomics captures every detail, delivering precision insights when it matters most.
Advanced machine learning deciphers complex cancer profiles, providing comprehensive insights in real-time. single cell Mult-iomics
High-resolution single cell analysis uncovers tumor heterogeneity and disease evolution at the molecular level providing actionable insights.
Tailored treatment strategies informed by real-world data utilizing AI-enhanced interpretation.
A comprehensive NGS panel covering 1,000+ genes with tissue or liquid biopsy input. OncoIndx® provides actionable insights for targeted therapy, immunotherapy, resistance detection, and clinical trial matching.
An integrated tissue–liquid–normal DNA test delivering somatic, germline, and CHIP classification in one assay. OncoIndx® Prime+ combines NGS, RNA fusion detection, and pharmacogenomics to support complex oncology cases.
A germline NGS test that identifies hereditary cancer risks across 11+ cancer types. OncoRisk® enables early intervention, family screening, and preventive care with the support of genetic counseling.
A cost-effective targeted NGS test covering guideline-recommended genes for major cancers like breast, lung, and colon. OncoTarget® enables personalized therapy decisions using deep sequencing and customizable gene panels.
An advanced genomic test designed to detect homologous recombination deficiency (HRD) and support the use of PARP inhibitors. OncoHRD® delivers precise HRD scoring through LOH, TAI, and LST metrics across 50+ genes.
A liquid biopsy test for longitudinal cancer monitoring, using CTC and ctDNA analysis to track treatment response, detect resistance, and identify minimal residual disease (MRD). Ideal for real-time, non-invasive follow-up.
The Technology
Machine learning models trained on oncology-specific data to enable real-time molecular analysis and predictive insights.
High-resolution insights from individual tumor cells, integrating genomic, transcriptomic, and proteomic data to reveal tumor behavior and heterogeneity.
Advanced tools to process and interpret multi-omics data—connecting biological complexity to actionable clinical insights.
Automated, algorithm-driven image analysis that improves diagnostic accuracy, consistency, and speed in tissue evaluation.
Immediate delivery of molecular findings to support timely decisions in research, drug design and development , and treatment planning.
A scalable, modular platform for managing precision oncology data across clinical trials, research studies, and lab workflows.
Our Solutions
At 1Cell.Ai, we deliver scalable, AI-powered solutions designed to meet the unique needs of clinicians and oncologists, pharma and bio-pharma industry partners, KOLs, and researchers, and for cancer patients. Our platform turns complex molecular data into real-time, actionable insights—impacting care at every level.
For Clinicians & Oncologists
Non-invasive, real-time molecular alteration information to personalize therapy decisions and continuously monitor disease progression.
For Pharma and Bio-pharma Partners
Multi-omics data integration with true single cell resolution and AI analytics accelerate biomarker discovery, patient stratification, and targeted drug development.
For KOLs and Researchers
Tailored algorithms and advanced data models designed to solve specific clinical and research challenges in oncology.
For Cancer Patients
The ultimate beneficiaries—receiving earlier diagnoses, more personalized treatment and real-time treatment response and therapy monitoring and better long-term outcomes driven by science and AI.
Patient: 49-year-old male, non-smoker, diagnosed with Stage IV lung adenocarcinoma with multiple bilateral pulmonary nodules and liver metastases. Clinical Testing:Alterations: MET exon 14 skipping (splice-site
Patient: 7-year-old male with glioblastoma multiforme (WHO Grade IV) post–partial resection and chemoradiotherapy Clinical Testing:Alterations: TP53, CDKN2A, LATS1, ATM, BRCA2, RAD50, MSH2, MLH1, PMS2, XPC,
Patient: 55 years – Female with metastatic triple-negative breast carcinoma (ER–, PR–, HER2 1+) Clinical Testing:Alterations: TP53 (p.D281E), MSH3 (p.R454*), PIK3CA (p.E542K), SMAD4 (p.E307*), SMARCA4 (p.D1127H), NF2
Strategic Partnerships Driving Best-in-Class Innovation
